Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Down 55.0% in August

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a large decrease in short interest in August. As of August 31st, there was short interest totaling 20,320 shares, a decrease of 55.0% from the August 15th total of 45,169 shares. Based on an average daily volume of 31,148 shares, the short-interest ratio is currently 0.7 days. Approximately 1.0% of the company’s shares are short sold.

Xenetic Biosciences Stock Performance

Shares of Xenetic Biosciences stock traded down $2.07 during midday trading on Wednesday, reaching $2.20. 1,413,924 shares of the company’s stock traded hands, compared to its average volume of 35,787. The stock has a 50 day moving average of $3.34 and a 200-day moving average of $3.11. Xenetic Biosciences has a 12 month low of $1.87 and a 12 month high of $13.93. The company has a market cap of $5.05 million, a PE ratio of -1.87 and a beta of 2.23.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter. Xenetic Biosciences had a negative net margin of 75.90% and a negative return on equity of 40.62%. The company had revenue of $0.66 million for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Xenetic Biosciences presently has a consensus rating of “Sell”.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.